Global Pneumococcal Polysaccharide Vaccine
Market Report
2024
Pneumococcal Polysaccharide Vaccine Market Report 2024 (Global Edition)
the Global Pneumococcal Polysaccharide Vaccine market size was USD 8.90 Billion in 2022 and it is forecasted to reach USD 11.27 Billion. Pneumococcal Polysaccharide Vaccine Industry's Compound Annual Growth Rate will be 3.2% from 2023 to 2030.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Pneumococcal Polysaccharide Vaccine Market Report 2024.
Global Pneumococcal Polysaccharide Vaccine Market Report 2024 Market Size Split by Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine, Others), by Product Type (Prevnar ...
As per Cognitive Market Research's latest published report, the Global Pneumococcal Polysaccharide Vaccine market size was USD 8.90 Billion in 2022 and it is forecasted to reach USD 11.27 Billion. Pneumococcal Polysaccharide Vaccine Industry's Compound Annual Growth Rate will be 3.2% from 2023 to 2030.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Pneumococcal Polysaccharide Vaccine Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 3.2% |
| Market Split by Vaccine Type |
|
| Market Split by Product Type |
|
| Market Split by Sector |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Pneumococcal Polysaccharide Vaccine industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Pneumococcal Polysaccharide Vaccine Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Pneumococcal Polysaccharide Vaccine Market Report Description
Introduction of Pneumococcal Polysaccharide Vaccine Market
Pneumococcal is caused by the bacteria Streptococcus pneumoniae Pneumococcal which causes many types of illness, this disease leads to dangerous infections. Pneumococcal diseases are caused by the spread of direct contact with mucus or saliva and airborne droplets. People of any age and having specific medical problems are at high risk to get affected by types of pneumococcal diseases. Some of the diseases are considered invasive, Invasive pneumococcal diseases are a group of illnesses caused by pneumococcus bacteria. Pneumococcal pneumonia can be also caused by at least being at a 65-year age or a person is affected by chronic diseases. Risk factors of pneumococcal pneumonia are Diabetes, Asthma, Chronic obstructive pulmonary disease (COPD), Suppressed immune system, Smoking, and Alcoholism. The Pneumococcal Polysaccharide Vaccine (PPSV23) protects against 23 types of bacteria that cause bacterial pneumococcal disease. The usage of pneumococcal vaccine in COVID-19 boosts the Global Pneumococcal Polysaccharide Vaccine Market growth.
Factor Driving the Pneumococcal Polysaccharide Vaccine Market
- The increasing partnership of manufacturers is driving the Global Pneumococcal Polysaccharide Vaccine Market
The rising partnership between the manufacturers and numerous governments countries is projected to drive the growth of the Global Pneumococcal Polysaccharide Vaccine Market. The manufacturers are investing in new projects, and focusing on diseases not having vaccines for different age groups, for the people affected in the underdeveloped or developing countries. This helps the companies like GlaxoSmithKline plc., to sustain their position in the vaccine business in the forecast period. For instance, the data by UNICEF (United Nations International Children’s Emergency Fund) over 80% of the countries eligible to access PCV using the Advance market commitment (AMC) have introduced the vaccine into their national immunization programs.
In addition, the increasing prevalence of pneumonia globally is one of the major aspects driving the Global Pneumococcal Polysaccharide Vaccine Market growth. The demand rising for medications for the treatment of illnesses related to diseases like breathing issues, and the economic help of the researchers for the advancements in novel interventions or treatments related to the market growth. The increasing awareness of novel pneumococcal vaccines and rising investments of government and rising awareness of healthcare for the successful treatment of the disease fuel the market growth.
Restraining Factors of Global Pneumococcal Polysaccharide Vaccine Market
-
The increasing cost of vaccines is hampering the Global Pneumococcal Polysaccharide Vaccine Market
The increasing cost of numerous pneumococcal vaccines, particularly PCV13 is the source of various investing agencies and the players in the public and private sector is hampering the market growth. In 2013-2014, the US government purchased the PCV13 vaccine from Pfizer for around US$ 284.5 for a single child's inoculation. Furthermore, in other countries such as India, PCV13 and PCV10 are priced in the private market at roughly US$ 59/dose and US$ 28/dose, respectively, with three doses required for full vaccination (as reported by Médecins Sans Frontières (MSF), a humanitarian organization). Pfizer's Prevenar13 pneumococcal vaccination received a patent extension from the Indian Patent Office in August 2017.
Impact of COVID-19 on Global Pneumococcal Polysaccharide Vaccine Market
The outbreak of COVID-19 in December 2019, the virus has spread all over the globe and WHO declared the world health emergency in January 2020. According to the most recent set of full worldwide kid immunization records, which are the first official figures to incorporate global service disruptions due to the COVID-19 pandemic, the majority of countries reported a fall in childhood vaccination rates in 2020. Additionally, according to a Public Health England report published in the first wave of COVID-19 PHE conducted an online survey to find out the parent’s experience with the routine vaccinations of children.
We have various report editions of Pneumococcal Polysaccharide Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Pneumococcal Polysaccharide Vaccine Market Insights Video
Competitive landscape of Global Pneumococcal Polysaccharide Vaccine Market
The major players in the market are Pfizer, Inc., Merck & Co. Inc., GlaxoSmithKline plc., IG chem Ltd., Sk Bioscience, Shenzhen Kangtai biological products co., ltd., walvax biotechnology co., ltd., Pnuvax incorporated, serum institute of India Pvt. Ltd., Panacea biotech limited.
Pneumococcal Polysaccharide Vaccine Industry News
- May 2021, Pfizer begins testing the use of the pneumococcal vaccine along with the COVID-19 booster shoot.
Pfizer announced the pneumococcal vaccine use with the COVID-19 booster shoot. The study includes 600 adults over 65 years who will be recruited from the late-stage study of the Pfizer-BioNTech COVID-19 vaccine and will have received their second dose of the vaccine at least six months prior to entering the co-administration study.
The vaccine maker Biological (BE) announced that the Subject expert committee of the Center Drug Standard Control Organization has approved the phase-3 infants clinical trial data and recommended the manufacture of its Pediatric vaccine streptococcus pneumonia infection in a single.
Top Companies Market Share in Pneumococcal Polysaccharide Vaccine Industry: (In no particular order of Rank)
- Pfizer Inc.
- Merck & Co. Inc.
- GlaxoSmithKline plc.
- IG chem Ltd.
- Sk Bioscience
- Shenzhen Kangtai biological products co. ltd.
- walvax biotechnology co. ltd.
- Pnuvax incorporated
- serum institute of India Pvt. Ltd.
- Panacea biotech limited
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
The North America holds the largest share in the Global Pneumococcal Polysaccharide Vaccine Market.
The developed healthcare infrastructure, rapidly increasing geriatric population, and increasing prevalence of infectious diseases are spiking the growth of the market in the region. Additionally, the presence of major players in the region coupled with the advanced technology treatment and government schemes and investment in the healthcare sector is fuelling the market growth in the region and is projected to sustain its position during the forecast period.
The current report Scope analyzes Pneumococcal Polysaccharide Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Pneumococcal Polysaccharide Vaccine Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Pneumococcal Polysaccharide Vaccine Market Analysis
Global Pneumococcal Polysaccharide Vaccine Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Pneumococcal Polysaccharide Vaccine Industry growth. Pneumococcal Polysaccharide Vaccine market has been segmented with the help of its Vaccine Type, Product Type Sector, and others. Pneumococcal Polysaccharide Vaccine market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
The pneumococcal conjugate vaccine segment control the global Pneumococcal Polysaccharide Vaccine Market
The pneumococcal conjugate vaccine is used to vaccinate children under 2 years old. The parents are concerned about their infant’s health and the government initiative funding for different types of vaccines is fuelling the market growth. Increasing awareness of different types of vaccines by the government and healthcare institutes is increasing the growth of the segment in the market. The PCV segments hold the highest revenue share owing to the use of vaccines among the population as the rising prevalence of pneumonia, which consist of children below 5 and above 50 years.
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
- Others
Pneumococcal Polysaccharide Vaccine Market Share (%) by Vaccine Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pneumococcal Polysaccharide Vaccine Industry. Request a Free Sample PDF!
Product Type Segment Analysis of Pneumococcal Polysaccharide Vaccine Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Pneumococcal Polysaccharide Vaccine from 2019 to 2031. This will also help to analyze the demand for Pneumococcal Polysaccharide Vaccine across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key Product Type of Pneumococcal Polysaccharide Vaccine are:
- Prevnar 13
- Synflorix
- Pneumovax 23
- Others
Pneumococcal Polysaccharide Vaccine Market Share (%) by Product Type in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Pneumococcal Polysaccharide Vaccine Sector Segment Analysis
- Private hospitals
- Clinics
- Others
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.
The Global Pneumococcal Polysaccharide Vaccine Market is witnessing significant growth in the near future.
In 2023, the Pneumococcal Conjugate Vaccine segment accounted for noticeable share of global Pneumococcal Polysaccharide Vaccine Market and is projected to experience significant growth in the near future.
The Prevnar 13 segment is expected to expand at the significant CAGR retaining position throughout the forecast period.
Some of the key companies Pfizer Inc. , GlaxoSmithKline plc. and others are focusing on its strategy building model to strengthen its product portfolio and expand its business in the global market.
Frequently Asked Questions (FAQs)
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Pneumococcal Polysaccharide Vaccine Market
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Pneumococcal Polysaccharide Vaccine Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Vaccine Type | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine, Others |
| Product Type | Prevnar 13, Synflorix, Pneumovax 23, Others |
| Sector | Private hospitals, Clinics, Others |
| List of Competitors | Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., IG chem Ltd., Sk Bioscience, Shenzhen Kangtai biological products co. ltd., walvax biotechnology co. ltd., Pnuvax incorporated, serum institute of India Pvt. Ltd., Panacea biotech limited |
This chapter will help you gain GLOBAL Market Analysis of Pneumococcal Polysaccharide Vaccine. Further deep in this chapter, you will be able to review Global Pneumococcal Polysaccharide Vaccine Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Pneumococcal Polysaccharide Vaccine Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Pneumococcal Polysaccharide Vaccine Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size By Region
-
-
1.3 Global Pneumococcal Polysaccharide Vaccine Market Size By Vaccine Type 2019 -2031
-
1.3.1 Pneumococcal Conjugate Vaccine Market Size
-
1.3.2 Pneumococcal Polysaccharide Vaccine Market Size
-
1.3.3 Others Market Size
-
-
1.4 Global Pneumococcal Polysaccharide Vaccine Market Size By Product Type 2019 -2031
-
1.4.1 Prevnar 13 Market Size
-
1.4.2 Synflorix Market Size
-
1.4.3 Pneumovax 23 Market Size
-
1.4.4 Others Market Size
-
-
1.5 Global Pneumococcal Polysaccharide Vaccine Market Size By Sector 2019 -2031
-
1.5.1 Private hospitals Market Size
-
1.5.2 Clinics Market Size
-
1.5.3 Others Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Vaccine Type
-
1.7.3 Global Market Revenue Split By Product Type
-
1.7.4 Global Market Revenue Split By Sector
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Pneumococcal Polysaccharide Vaccine Market Size 2019 - 2031
-
2.1.1 North America Pneumococcal Polysaccharide Vaccine Market Size By Country 2019 - 2031
-
2.1.2 North America Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
2.1.2.1 North America Pneumococcal Conjugate Vaccine Market Size
-
2.1.2.2 North America Pneumococcal Polysaccharide Vaccine Market Size
-
2.1.2.3 North America Others Market Size
-
-
2.1.3 North America Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
2.1.3.1 North America Prevnar 13 Market Size
-
2.1.3.2 North America Synflorix Market Size
-
2.1.3.3 North America Pneumovax 23 Market Size
-
2.1.3.4 North America Others Market Size
-
-
2.1.4 North America Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
2.1.4.1 North America Private hospitals Market Size
-
2.1.4.2 North America Clinics Market Size
-
2.1.4.3 North America Others Market Size
-
-
-
2.2 Add-Ons: Customize the Report Edition
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
-
2.2.1 North America Company Market Share 2019 till 2023
-
2.2.2 Qualitative Analysis for North America Market
Qualitative Analysis for the North America Market: North America Pneumococcal Polysaccharide Vaccine Market Trends North America Pneumococcal Polysaccharide Vaccine Technological Road Map North America Pneumococcal Polysaccharide Vaccine Market Drivers North America Pneumococcal Polysaccharide Vaccine Market Restraints North America Pneumococcal Polysaccharide Vaccine Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
-
-
2.3 Executive Summary North America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary North America Market (2019 vs 2024 vs 2031)
-
2.3.1 North America Market Summary 2019 vs 2024 vs 2031
-
2.3.2 North America Market Revenue Split By Vaccine Type
-
2.3.3 North America Market Revenue Split By Product Type
-
2.3.4 North America Market Revenue Split By Sector
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Pneumococcal Polysaccharide Vaccine Market Size 2019 - 2031
-
3.1.1 Europe Pneumococcal Polysaccharide Vaccine Market Size By Country 2019 - 2031
-
3.1.2 Europe Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
3.1.2.1 Europe Pneumococcal Conjugate Vaccine Market Size
-
3.1.2.2 Europe Pneumococcal Polysaccharide Vaccine Market Size
-
3.1.2.3 Europe Others Market Size
-
-
3.1.3 Europe Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
3.1.3.1 Europe Prevnar 13 Market Size
-
3.1.3.2 Europe Synflorix Market Size
-
3.1.3.3 Europe Pneumovax 23 Market Size
-
3.1.3.4 Europe Others Market Size
-
-
3.1.4 Europe Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
3.1.4.1 Europe Private hospitals Market Size
-
3.1.4.2 Europe Clinics Market Size
-
3.1.4.3 Europe Others Market Size
-
-
-
3.2 Add-Ons: Customize the Report Edition
-
3.2.1 Europe Company Market Share 2019 till 2023
-
3.2.2 Qualitative Analysis for Europe Market
-
-
3.3 Executive Summary Europe Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Europe Market (2019 vs 2024 vs 2031)
-
3.3.1 Europe Revenue Market Summary 2019 vs 2024 vs 2031
-
3.3.2 Europe Market Revenue Split By Vaccine Type
-
3.3.3 Europe Market Revenue Split By Product Type
-
3.3.4 Europe Market Revenue Split By Sector
-
Chapter 4 Asia-Pacific Market Analysis
-
4.1 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size 2019 - 2031
-
4.1.1 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
4.1.2.1 Asia Pacific Pneumococcal Conjugate Vaccine Market Size
-
4.1.2.2 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size
-
4.1.2.3 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
4.1.3.1 Asia Pacific Prevnar 13 Market Size
-
4.1.3.2 Asia Pacific Synflorix Market Size
-
4.1.3.3 Asia Pacific Pneumovax 23 Market Size
-
4.1.3.4 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
4.1.4.1 Asia Pacific Private hospitals Market Size
-
4.1.4.2 Asia Pacific Clinics Market Size
-
4.1.4.3 Asia Pacific Others Market Size
-
-
-
4.2 Add-Ons: Customize the Report Edition
-
4.2.1 Asia Pacific Company Market Share 2019 till 2023
-
4.2.2 Qualitative Analysis for Asia Pacific Market
-
-
4.3 Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Asia Pacific Market (2019 vs 2024 vs 2031)
-
4.3.1 Asia Pacific Market Summary 2019 vs 2024 vs 2031
-
4.3.2 Asia Pacific Market Revenue Split By Vaccine Type
-
4.3.3 Asia Pacific Market Revenue Split By Product Type
-
4.3.4 Asia Pacific Market Revenue Split By Sector
-
Chapter 5 South America Market Analysis
-
5.1 South America Pneumococcal Polysaccharide Vaccine Market Size 2019 - 2031
-
5.1.1 South America Pneumococcal Polysaccharide Vaccine Revenue Market Size By Country 2019 - 2031
-
5.1.2 South America Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
5.1.2.1 South America Pneumococcal Conjugate Vaccine Market Size
-
5.1.2.2 South America Pneumococcal Polysaccharide Vaccine Market Size
-
5.1.2.3 South America Others Market Size
-
-
5.1.3 South America Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
5.1.3.1 South America Prevnar 13 Market Size
-
5.1.3.2 South America Synflorix Market Size
-
5.1.3.3 South America Pneumovax 23 Market Size
-
5.1.3.4 South America Others Market Size
-
-
5.1.4 South America Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
5.1.4.1 South America Private hospitals Market Size
-
5.1.4.2 South America Clinics Market Size
-
5.1.4.3 South America Others Market Size
-
-
-
5.2 Add-Ons: Customize the Report Edition
-
5.2.1 South America Company Market Share 2019 till 2023
-
5.2.2 Qualitative Analysis for South America Market
-
-
5.3 Executive Summary South America Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary South America Market (2019 vs 2024 vs 2031)
-
5.3.1 South America Market Summary 2019 vs 2024 vs 2031
-
5.3.2 South America Market Revenue Split By Vaccine Type
-
5.3.3 South America Market Revenue Split By Product Type
-
5.3.4 South America Market Revenue Split By Sector
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Pneumococcal Polysaccharide Vaccine Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Pneumococcal Polysaccharide Vaccine Revenue Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
6.1.2.1 Middle East and Africa Pneumococcal Conjugate Vaccine Market Size
-
6.1.2.2 Middle East and Africa Pneumococcal Polysaccharide Vaccine Market Size
-
6.1.2.3 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
6.1.3.1 Middle East and Africa Prevnar 13 Market Size
-
6.1.3.2 Middle East and Africa Synflorix Market Size
-
6.1.3.3 Middle East and Africa Pneumovax 23 Market Size
-
6.1.3.4 Middle East and Africa Others Market Size
-
-
6.1.4 Middle East and Africa Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
6.1.4.1 Middle East and Africa Private hospitals Market Size
-
6.1.4.2 Middle East and Africa Clinics Market Size
-
6.1.4.3 Middle East and Africa Others Market Size
-
-
-
6.2 Add-Ons: Customize the Report Edition
-
6.2.1 Middle East and Africa Company Market Share 2019 till 2023
-
6.2.2 Qualitative Analysis for Middle East and Africa Market
-
-
6.3 Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary Middle East and Africa Market (2019 vs 2024 vs 2031)
-
6.3.1 Middle East and Africa Market Summary 2019 vs 2024 vs 2031
-
6.3.2 Middle East and Africa Market Revenue Split By Vaccine Type
-
6.3.3 Middle East and Africa Market Revenue Split By Product Type
-
6.3.4 Middle East and Africa Market Revenue Split By Sector
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Pneumococcal Polysaccharide Vaccine Market Size by Vaccine Type 2019 -2031
-
7.1.2 Country 1Pneumococcal Polysaccharide Vaccine Market Size by Product Type 2019 -2031
-
7.1.3 Country 1Pneumococcal Polysaccharide Vaccine Market Size by Sector 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Pneumococcal Polysaccharide Vaccine Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Pfizer Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Merck & Co. Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 GlaxoSmithKline plc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 IG chem Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Sk Bioscience
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Shenzhen Kangtai biological products co. ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 walvax biotechnology co. ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Pnuvax incorporated
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 serum institute of India Pvt. Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Panacea biotech limited
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Vaccine Type Analysis 2019 -2031, will provide market size split by Vaccine Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Vaccine Type Analysis 2019 -2031
-
10.1 Pneumococcal Conjugate Vaccine
-
10.1.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Pneumococcal Conjugate Vaccine 2019 -2031
-
-
10.2 Pneumococcal Polysaccharide Vaccine
-
10.2.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Pneumococcal Polysaccharide Vaccine 2019 -2031
-
-
10.3 Others
-
10.3.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Product Type Analysis 2019 -2031
-
11.1 Prevnar 13
-
11.1.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Prevnar 13 2019 - 2031
-
-
11.2 Synflorix
-
11.2.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Synflorix 2019 - 2031
-
-
11.3 Pneumovax 23
-
11.3.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Pneumovax 23 2019 - 2031
-
-
11.4 Others
-
11.4.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Sector Analysis 2019 -2031
-
12.1 Private hospitals
-
12.1.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Private hospitals 2019 -2031
-
-
12.2 Clinics
-
12.2.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Clinics 2019 -2031
-
-
12.3 Others
-
12.3.1 Global Pneumococcal Polysaccharide Vaccine Revenue Market Size and Share by Others 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Pneumococcal Polysaccharide Vaccine market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Pneumococcal Polysaccharide Vaccine Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Pneumococcal Polysaccharide Vaccine Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Pneumococcal Polysaccharide Vaccine Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Pneumococcal Polysaccharide Vaccine Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Pneumococcal Polysaccharide Vaccine Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Pneumococcal Polysaccharide Vaccine Market
Key Questions Answered By Pneumococcal Polysaccharide Vaccine Market Report 2024
| Why Pneumococcal Conjugate Vaccine have a significant impact on Pneumococcal Polysaccharide Vaccine market? |
| What are the key factors affecting the Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine of Pneumococcal Polysaccharide Vaccine Market? |
| What is the CAGR/Growth Rate of Prevnar 13 during the forecast period? |
| By type, which segment accounted for largest share of the global Pneumococcal Polysaccharide Vaccine Market? |
| Which region is expected to dominate the global Pneumococcal Polysaccharide Vaccine Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
